With 1.51 million shares changed hands, the volume of the stock remained lighter than its average volume of 2.94 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $0.3349 whereas the lowest price it dropped to was $0.3205. The 52-week range on CYBN shows that it touched its highest point at $0.73 and its lowest point at $0.21 during that stretch.
Price Performance and Earnings:
Three-month performance surged to 20.00% while six-month performance fell -15.38%. The stock lost -54.43% in the past year, while it has gained 11.07% so far this year. A look at the trailing 12-month EPS for CYBN yields -0.25 with Next year EPS estimates of -0.19. For the next quarter, that number is -0.05. This implies an EPS growth rate of 36.70% for this year and 9.50% for next year.
Float and Shares Shorts:
At present, 206.16 million CYBN shares are outstanding with a float of 192.09 million shares on hand for trading. On Aug 30, 2023, short shares totaled 3.15 million, which was 1.34% higher than short shares on Jul 30, 2023. In addition to Mr. Eric So L.L.B., LLB as the firm’s Co-Founder, Pres & Exec. Chairman, Mr. Douglas L. Drysdale serves as its Chief Exec. Officer.
Other institutions hold — of CYBN, in contrast to — held by mutual funds. Shares owned by individuals account for –. With a 1.13% stake in CYBN, the Horizons Psychedelic Stock Index is the largest stakeholder. A total of 2,657,731 shares are owned by the mutual fund manager. The AdvisorShares Psychedelics ETF, which owns about 0.88% of CYBN stock, is the second-largest Mutual Fund holder. It holds 2,060,352 shares valued at 0.64 million. Simplify Propel Opportunities ETF holds 0.21% of the stake in CYBN, owning 500,000 shares worth 0.15 million.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on Jun 29, 2023, CYBN reported revenue of $0.00 and operating income of -$13.39M. The EBITDA in the recently reported quarter was -$13.56M and diluted EPS was -$0.07.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for CYBN since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With CYBN analysts setting a high price target of $10.00 and a low target of $0.74, the average target price over the next 12 months is $4.17. Based on these targets, CYBN could surge 2930.3% to reach the target high and rise by 124.24% to reach the target low. Reaching the average price target will result in a growth of 1163.64% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy.
Summary of Insider Activity:
Insiders traded CYBN stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has increased to 4 while that of sell transactions has remained unmoved to 0 over the past year. The total number of shares bought during that period was 5,718,574 while 0 shares were sold.